This project has been flagged by a community member as inappropriate due to reason below.*


Slingshot members are conducting a survey! The topic is:

Two Week Delay: Survey on Auvelity's potential in MDD, including what therapies in development are most exciting for treating patients.

Ticker(s): AXSM

Who's being surveyed?

The survey includes 30 Psychiatrists.

Survey Questions

How many patients with Major Depressive Disorder (MDD) do you see per month, on average?


What % of your patients with MDD have tried at least three different anti-depressants?


Have you prescribed Auvelity?


What percentage of your MDD patients would you prescribe Auvelity for?


How is the rapid onset of action and novel mechanism for an oral drug differentiated from bupropion?


Do you expect to be able to use compounded dextromethorphan + buproprion after approval? 


How many months do you expect on average for payor access/coverage for Auvelity to take?


What are the advantages of Auvelity for MDD? 


What are the disadvantages of Auvelity for MDD? 


What is the probability of success for the phase 3 trial of adjunctive Caplyta (lumateperone) for the treatment of MDD? 


What is the probability of success for the phase 2 trial of XEN1101 (kv7 channel modulator) for the treatment of MDD? 


What is the most exciting novel treatment under development for MDD?

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.